Background

Inflammatory bowel disease (IBD) can lead to debilitating and sometimes life-threatening complications. Bowel disorders (i.e. IBS & IBD) affect more than 64 millions of Americans for life with an onset age in adolescence & 20s. Current treatments for IBD only address the symptoms and are not curative, and they have potentially serious side effects.

Technology Overview

Researchers at the University of Manitoba have recently explored the utilization of Catestatin (CTS) to disrupt colonic microbiota composition. Animal data shows that intrathecal CTS treatment in mice with DSS induced Colitis positively modifies the balance of the bacterial community composition without affecting the richness of the bacterial species neither in fecal and colonic samples.

Backed by an issued US patent, the results show that CTS treatment holds potential as a new antibacterial treatment for disorders associated with bacterial balance in the gut.

Benefits

Does not affect functional diversity or stability of beneficial bacteria
In vivo data suggest higher likelihood of clinical success
Promising for:

Prevention and/or treatment for IBS, IBD, obesity & type 2 diabetes
Reduction on frequency of attacks for IBD &/or IBS
Reduction of one or more symptoms
Reduction of symptoms severity
Increase the length of time between symptoms

Applications

Prevention and / or treatment for Inflammatory Bowel Disease (IBD)
Prevention and / or treatment for Obesity and Type 2 Diabetes

Opportunity

Currently looking for research partners
Technology is available for exclusive licensing

Human Catestatin Therapy - A Treatment for Gut Microbiota Dysbiosis

Patents

IP Status

Seeking